INDIANAPOLIS, August 23, 2026, 06:24 EDT
- Lilly gained 6.38% over the past week, increasing its market capitalization by about $67.1 billion.
- Friday’s closing price of $1,255.40 was just 4.43% below the analysts’ consensus target of $1,311.
- Second-quarter sales for Mounjaro and Zepbound reached $14.87 billion.
- At this valuation, price realization, competition from oral drugs, and execution have become more critical factors.
Eli Lilly and Company NYSE:LLY saw its market capitalization rise by about $67.1 billion over the past week. Shares climbed 6.38% to $1,255.40 as of Friday’s close, with 891.36 million shares outstanding. The stock now trades just 4.43% under the consensus one-year price target from Wall Street. The gap in valuation has rapidly closed.
The decision is significant as Lilly’s operating momentum continues to be strong. However, the present valuation already factors in much of this performance. Investors are currently pricing in ongoing volume increases, additional production from new facilities, and successful product rollouts.
| Session | Close | Daily move | Volume |
|---|---|---|---|
| Aug. 17 | $1,183.16 | up 0.25% | 1.74 million |
| Aug. 18 | $1,225.73 | up 3.60% | 2.44 million |
| Aug. 19 | $1,280.34 | up 4.46% | 4.40 million |
| Aug. 20 | $1,244.40 | down 2.81% | 2.31 million |
| Aug. 21 | $1,255.40 | up 0.88% | 2.49 million |
Lilly shares posted gains on Friday after a turbulent three-day span. The stock hit an all-time intraday high of $1,292.65 on Wednesday before slipping 2.81% on Thursday. By the close, shares were 2.88% off the recent high. Trading activity peaked on Wednesday.
Earnings remain robust. Revenue for the second quarter climbed 48% to $22.97 billion. Volumes saw a 60% increase, while realized prices declined by 13%. This combination highlights the importance of manufacturing scale and supply for the future phase.
| Operating measure | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Total revenue | $22.97 billion | $15.56 billion | up 48% |
| Mounjaro sales | $9.94 billion | $5.20 billion | up 91% |
| Zepbound sales | $4.93 billion | $3.38 billion | up 46% |
| Non-GAAP EPS | $8.38 | $6.31 | up 33% |
Mounjaro and Zepbound contributed a combined $14.87 billion. This accounted for nearly 65% of quarterly revenue. Lilly lifted its 2026 sales outlook to a range of $85 billion to $87 billion, and projected non-GAAP earnings per share of $35.50 to $36.50.
Chief Executive David Ricks stated Lilly achieved “48% revenue growth and raised our full-year guidance.” The firm is allocating an additional $4.5 billion to manufacturing operations in Indiana. Greater supply could increase volume but heightens the risk associated with any failed launch. Company statement
| Analyst measure | Value | Implied move from $1,255.40 |
|---|---|---|
| Consensus recommendation | Buy | Based on responses from 29 analysts |
| Average target | $1,311 | Up 4.43% |
| Median target | $1,372 | Up 9.29% |
| High target | $1,600 | Up 27.45% |
| Low target | $850 | Down 32.29% |
The analyst range stands out as a clear valuation signal. The $750 gap amounts to nearly 60% of the share price from Friday. On Friday, Bank of America issued a $1,344 price target. BMO lifted its target to $1,400 earlier in the week. Berenberg’s hold rating is set at $1,220, which is below current trading levels.
Progress in the pipeline may help sustain the premium. Retatrutide achieved weight loss reaching 22.6% in two additional Phase 3 studies. Lilly aims to seek U.S. regulatory approval in the first quarter of 2027. The complete data set now includes obesity as well as associated conditions.
Rivals are also taking action. Novo Nordisk NYSE:NVO has launched a study with 450 participants to examine reduced maintenance doses for its oral Wegovy treatment. The aim is to offer greater flexibility in response to worries about cost and side effects. The study is scheduled to continue until 2028.
Risks include the potential for lower realized prices to counteract gains in prescription volumes. Delays in production, stricter reimbursement policies, or slower Foundayo adoption may reduce projections. Lilly is additionally exposed to safety, oversight, and legal risks tied to its focused obesity portfolio.
Markets will not open on Sunday. The key question is if buyers will hold the line at Thursday’s $1,243.23 low. Upcoming U.S. personal income and inflation releases this week could influence valuations for long-term healthcare. With the sector at $1.12 trillion, even slight multiple moves result in significant dollar shifts.
Related articles: NYSE:LLY
